Early Childhood Eczema and Uveitis: A Higher Relative Risk, but 94 Events Among 114,889 Children

November 9, 2026

Dr. Arsy #003 white 4 oz (120 g) jar in an original ski-lodge scene; AI-created editorial illustration.

DOCTOR’S NOTES · ECZEMA EVIDENCE

Uveitis is inflammation inside the eye, not another name for eczema on the eyelid. A large childhood study found an association with early-onset atopic dermatitis, while the actual event counts remained small. Parents need both parts of that finding.

What the 2025 study measured

The primary JAMA Ophthalmology cohort report used US electronic health records from 2004 through December 14, 2024. Early-onset eczema meant an AD diagnosis before age two. After propensity-score matching, there were 114,889 children in each group. Children with uveitis before the eczema diagnosis were excluded.

Matched group	Recorded uveitis events	Reported proportion	Mean follow-up
Early-onset AD	94/114,889	0.08%	6.0 years
Without AD	58/114,889	0.05%	6.6 years

The reported hazard ratio was 1.92, with a 95% confidence interval of 1.38–2.66. That relative comparison is not a statement that nearly two out of every hundred children developed uveitis. The observed proportions were less than one tenth of one percent over the study’s follow-up.

Rare events still deserve careful interpretation

The unequal average follow-up is one reason to retain the time-to-event analysis and avoid presenting the crude percentages as a precise annual risk. The estimates also apply to the identified record-based cohorts, not to every child with a transient dry patch or an unconfirmed eczema diagnosis.

Matching balanced measured characteristics, but it cannot reproduce random assignment. Diagnoses depended on codes, clinical contact and what was recorded. More frequent care could influence detection, and unmeasured factors could contribute to the association. The study cannot establish that eczema caused the eye inflammation.

What exclusion analyses can and cannot show

The association persisted in analyses excluding dupilumab users and in analyses excluding children with autoimmune conditions. Those checks make a simple explanation based entirely on those recorded factors less likely. They do not prove that every possible confounder was removed or that a medicine caused or prevented the outcome.

The finding is also not evidence that treating the skin with a particular moisturizer prevents uveitis. No such intervention was tested. The authors discuss considering ophthalmologic monitoring; the study did not compare screening programs or establish a fixed examination interval for every child with eczema.

A practical plan for parents

National Eye Institute guidance identifies blurred vision, floaters, eye pain, redness and light sensitivity as possible uveitis symptoms and advises seeing an eye doctor promptly. Some childhood cases may be quiet, so an absence of obvious complaints is not a diagnostic test.

Ask the child’s clinician whether eczema severity, other conditions, symptoms or treatment history warrant an eye assessment. For school and sports, note new avoidance of bright light, visual complaints or persistent eye discomfort and communicate those observations without trying to diagnose the cause at home.

Do not use leftover eye drops or put cosmetic cream into the eye. An eye examination distinguishes internal inflammation from other causes of irritation. Our childhood cataract article discusses another eye outcome with a different definition and risk estimate.

Where daily moisture care fits

Dr. Arsy Moisturizer #003, 4 oz (120 g) is a cosmetic moisturizer for hydration, moisture-barrier support and dry-skin comfort. It does not treat, cure or prevent eczema and was not the intervention in this research. These findings do not establish infant suitability or pediatric efficacy for #003. A child’s clinician can advise on appropriate moisture care.